Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
about
Perspectives on the discovery of NOTCH2-specific inhibitors.Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells.Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.Targeting Notch signalling pathway of cancer stem cells.
P2860
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@en
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@nl
type
label
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@en
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@nl
prefLabel
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@en
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@nl
P2093
P2860
P1476
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
@en
P2093
Deric M Park
Edward Pan
Jeffrey G Supko
Jinkyu Jung
Nicholas A Butowski
Serena Desideri
Stuart Grossman
Thomas J Kaley
Timothy Cloughesy
P2860
P2888
P304
P356
10.1007/S11060-016-2263-1
P577
2016-11-08T00:00:00Z
P6179
1004035008